Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma (Q39372518)

11 September 2017

Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma (English)

1 reference

11 September 2017

1 reference

1 reference

1 reference

1

Gerhard Moldenhauer

1 reference

11 September 2017

Alexei V Salnikov

2

1 reference

11 September 2017

Sandra Lüttgau

3

1 reference

11 September 2017

Ingrid Herr

4

1 reference

11 September 2017

Jan Anderl

5

1 reference

11 September 2017

Heinz Faulstich

6

1 reference

11 September 2017

language of work or name

English

0 references

publication date

27 March 2012

1 reference

Journal of the National Cancer Institute

11 September 2017

1 reference

11 September 2017

104

1 reference

11 September 2017

8

1 reference

11 September 2017

622-634

1 reference

11 September 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Surgery insight: surgical management of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

EpCAM (CD326) finding its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

The biology of the 17-1A antigen (Ep-CAM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Frequent EpCam protein expression in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Phenotypic characterization of human colorectal cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Identification of pancreatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

EpCAM: A New Therapeutic Target for an Old Cancer Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Antibody-maytansinoid conjugates designed to bypass multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Antibody-drug conjugates: targeted drug delivery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Amatoxins, Phallotoxins, Phallolysin, and Antamanide: The Biologically Active Components of PoisonousAmanitaMushroom

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Ribosomal biosynthesis of the cyclic peptide toxins of Amanita mushrooms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Animal DNA-dependent RNA polymerases 11. Mechanism of the inhibition of RNA polymerases B by amatoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

alpha-Amanitin induced apoptosis in primary cultured dog hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Protein conjugates of fungal toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Molecular characterization and inhibition of amanitin uptake into human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Toxic action of a phalloidin-albumin conjugate on cells with a high protein uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJS140

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJS140

1 reference

11 September 2017

1 reference